51
|
Nirwane A, Majumdar A. Resveratrol and pterostilbene attenuated smokeless tobacco induced cardiovascular aberrations in estrogen deficient female rats. Toxicol Res (Camb) 2016; 5:1604-1618. [PMID: 30090461 PMCID: PMC6062250 DOI: 10.1039/c6tx00225k] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2016] [Accepted: 08/02/2016] [Indexed: 01/14/2023] Open
Abstract
This study evaluated the impact of resveratrol (RSV) and pterostilbene (PT) on the aqueous extract of smokeless tobacco (AEST) induced cardiovascular aberrations in estrogen deficient female Sprague-Dawley rats. Exposure to 4-vinylcyclohexene diepoxide (VCD) (80 mg kg-1, i.p.) for 30 days induces estrogen deficiency. The rats were administered AEST alone or AEST along with resveratrol and/or pterostilbene. Several markers of cardiovascular health were estimated to evaluate the repercussion of the exposures. RSV and PT per se and in combination significantly reversed the derangements caused by AEST. RSV decreased the atherogenic index and systolic blood pressure and normalized ECG. RSV and PT treatment markedly decreased aortic collagen, cardiac-carbonylated proteins, serum creatine-kinase, cholesterol, LDH, LDL, VLDL, CRP and TNF-α levels. Conversely, they increased serum nitrate-nitrite and HDL levels. The drugs improved the gene expression of SIRT1, PGC-1α, PPAR-α, TFAM, NRF-1 and mtDNA in the cardiac tissue. However, the expression of SIRT1 was not modified by PT. These favorable effects were comparable to those of estradiol therapy. Histopathological outcomes also corroborated these benefits. Thus, resveratrol and pterostilbene abrogated the deleterious effects of AEST on cardiovascular parameters in estrogen deficient female rats.
Collapse
|
52
|
Dawson P, Vijyakumar K, Majumdar A. Bone health in steroid treated Duchenne muscular dystrophy: A regional case series from the Southwest of the UK. Neuromuscul Disord 2016. [DOI: 10.1016/j.nmd.2016.06.349] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
53
|
Forrester N, Greenslade M, Buxton C, Norman A, Majumdar A. A novel homozygous frameshift deletion in the SH3TC2 gene in a patient with Charcot–Marie–Tooth (CMT) type 4C and severe ataxia. Neuromuscul Disord 2016. [DOI: 10.1016/j.nmd.2016.06.202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
54
|
Ashworth J, Doran N, Burrows E, Morgan A, Majumdar A, Thomas-Unsworth S. Living well with a neuromuscular disease: A newly established course for patients and their families. Neuromuscul Disord 2016. [DOI: 10.1016/j.nmd.2016.06.229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
55
|
Abbott D, Prescott H, Forbes K, Fraser J, Majumdar A. Men with Duchenne muscular dystrophy and end of life planning. Neuromuscul Disord 2016; 27:38-44. [PMID: 27816330 DOI: 10.1016/j.nmd.2016.09.022] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2016] [Revised: 09/14/2016] [Accepted: 09/26/2016] [Indexed: 10/20/2022]
Abstract
There is very limited evidence about the views of men with Duchenne muscular dystrophy (DMD) and end of life issues including death and dying. Studies have shown the physiological and psychological benefits of talking about and planning for end of life. Despite policy documents and guidance in the UK about end of life planning, there is consensus on the need for improvement. The study reported here is a qualitative one with 15 men with DMD (aged 20-45 years). Participants could not recall any significant conversations with clinicians about end of life and assumed that clinicians were reluctant to discuss the issue. The men in the study wanted to be given proactive cues that they could bring up topics such as death and dying and wanted to have these conversations with clinicians who combined expert knowledge about the condition as well as good listening skills. Topics of interest to participants included likely nature and place of death; practical planning for funerals and wills; and sources of information and support. Emotional or psychological support to think about end of life was not routinely offered and participants found it very difficult to discuss these issues with family members. The study suggests that more could be done to encourage clinicians, men with Duchenne, family members and the wider NMD community to pay attention to end of life planning issues and the associated need for emotional support and high quality interactions between patients and clinicians.
Collapse
|
56
|
Balasubramanian S, R M, Thej C, R B, Walvekar A, Swamynathan P, SundarRaj S, Gupta P, Majumdar A. Evaluation of Potency and Efficacy of Stempeucel®—Allogeneic Pooled Human Mscs in a Preclinical Model of Limb Ischemia. Cytotherapy 2016. [DOI: 10.1016/j.jcyt.2016.03.230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
57
|
Majumdar A, Kitson MT, Roberts SK. Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Aliment Pharmacol Ther 2016; 43:1276-92. [PMID: 27087015 DOI: 10.1111/apt.13633] [Citation(s) in RCA: 122] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/26/2015] [Revised: 10/06/2015] [Accepted: 03/29/2016] [Indexed: 12/12/2022]
Abstract
BACKGROUND The burden of HCV cirrhosis is high and projected to increase significantly over the next decade. While interferon therapy is problematic in HCV cirrhosis, the era of direct-acting anti-viral (DAA) therapy provides effective treatment for patients with cirrhosis. AIM To systematically review the results of DAA therapy to date in patients with HCV cirrhosis, and highlight the ongoing challenges for DAA therapy in this population. METHODS A structured Medline search was conducted to obtain phase II and III HCV trials in patients with cirrhosis. Citations from review articles were cross-referenced and conference abstracts from EASL and AASLD liver meetings for the preceding 3 years were reviewed manually. Keywords used included hepatitis C, cirrhosis and the DAA's: sofosbuvir, ledipasvir, velpatasvir, grazoprevir, elbasvir, daclatasvir, beclabuvir, asunaprevir, simeprevir, paritaprevir, ombitasvir and dasabuvir. RESULTS Successful direct-acting anti-viral treatment is now possible in patients with HCV-related cirrhosis including those with liver decompensation with several regimens now offering sustained virological response (SVR) of 90-95%. Overall success rates in GT1 cirrhosis are excellent while GT3-infected patients with cirrhosis remain hard to cure. The pangenotypic combination of sofosbuvir and velpatasvir holds promise for GT3 cirrhosis achieving SVR of ~90%. CONCLUSIONS Potent DAA therapies provide much needed, safe and highly effective treatment options for persons with HCV cirrhosis including those previously deemed unsuitable for treatment. Combination therapy with two or more classes of drug is essential to achieve high efficacy and minimise viral resistance, with the role of ribavirin still under evaluation. However, several challenges remain including the hard-to-cure groups of GT3 cirrhosis and direct-acting anti-viral failures, and managing drug-drug interactions.
Collapse
|
58
|
Majumdar A, Gilliam B. Grazoprevir potassium. HCV NS3 NS4A protease inhibitor, Anti-hepatitis C virus drug. DRUG FUTURE 2016. [DOI: 10.1358/dof.2016.041.02.2382555] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
59
|
Rehman S, Challa S, Majumdar A. A preliminary analysis of 96 patients enrolled in the BAOMS National 3rd Molar Audit (N3MA) at Milton Keynes General Hospital (MKGH) NHS Foundation Trust. Br J Oral Maxillofac Surg 2015. [DOI: 10.1016/j.bjoms.2015.08.027] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
60
|
Baldwin C, Moore K, Steele C, Young C, Arakji M, Dudhiya N, Gilson A, Majumdar A. The effect of food fortification with or without oral nutritional supplements on energy and protein provision and intake in nursing home residents: a service evaluation. Clin Nutr ESPEN 2015; 10:e188-e189. [PMID: 28531498 DOI: 10.1016/j.clnesp.2015.03.029] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
61
|
Jana R, Maity B, Mallick S, Majumdar A, Singh P. Nanostructured Ionomeric Membranes for Direct Methanol Fuel Cell. INDIAN CHEMICAL ENGINEER 2015. [DOI: 10.1080/00194506.2015.1029294] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
62
|
Singh W, Shukla A, Deb S, Majumdar A. Energy efficient acquisition and reconstruction of EEG signals. ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. ANNUAL INTERNATIONAL CONFERENCE 2015; 2014:1274-7. [PMID: 25570198 DOI: 10.1109/embc.2014.6943830] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
In Wireless Body Area Networks (WBAN) the energy consumption is dominated by sensing and communication. Previous Compressed Sensing (CS) based solutions to EEG tele-monitoring over WBAN's could only reduce the communication cost. In this work, we propose a matrix completion based formulation that can also reduce the energy consumption for sensing. We test our method with state-of-the-art CS based techniques and find that the reconstruction accuracy from our method is significantly better and that too at considerably less energy consumption. Our method is also tested for post-reconstruction signal classification where it outperforms previous CS based techniques. At the heart of the system is an Analog to Information Converter (AIC) implemented in 65nm CMOS technology. The pseudorandom clock generator enables random under-sampling and subsequent conversion by the 12-bit Successive Approximation Register Analog to Digital Converter (SAR ADC). AIC achieves a sample rate of 0.5 KS/s, an ENOB 9.54 bits, and consumes 108 nW from 1 V power supply.
Collapse
|
63
|
Bhattacharya DS, Salkar MH, Majumdar A. Encumberance to the Treatment of Osteoporosis: Physicians and Patient Perception. VALUE IN HEALTH : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH 2014; 17:A772. [PMID: 27202846 DOI: 10.1016/j.jval.2014.08.322] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
|
64
|
Majumdar A, Fadiliah A, Vijayakumar K, Greenslade M, Kurian K. G.P.158. Neuromuscul Disord 2014. [DOI: 10.1016/j.nmd.2014.06.188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
65
|
Majumdar A, Vijayakumar K, Merrison A, Buxton C, Burton-Jones S, Crosby C, Antoniadi T. G.P.240. Neuromuscul Disord 2014. [DOI: 10.1016/j.nmd.2014.06.316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
66
|
Jia X, Shi F, Yan H, Sivagnanam S, Folkerts M, Yan Y, Majumdar A, Jiang S. SU-D-BRD-03: A Gateway for GPU Computing in Cancer Radiotherapy Research. Med Phys 2014. [DOI: 10.1118/1.4887882] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
67
|
Gupta P, Chullikana A, Rajkumar M, Krishna M, Dutta S, Sarkar U, Desai S, Radhakrishnan R, Dhar A, Balasubramanian S, Kumar U, Baikunje U, Prasanth K, Anthony N, Majumdar A. Role of bone marrow derived allogeneic mesenchymal stromal cells (stempeucel ®) in critical limb ischemia due to buerger's disease – efficacy and safety results of non-randomized, open label, multicentric, dose ranging, phase ii study in India. Cytotherapy 2014. [DOI: 10.1016/j.jcyt.2014.01.295] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
68
|
Sanyal D, Majumdar A. Low dose liraglutide in Indian patients with type 2 diabetes in the real world setting. Indian J Endocrinol Metab 2013; 17:S301-3. [PMID: 24251194 PMCID: PMC3830340 DOI: 10.4103/2230-8210.119629] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
Liraglutide, a human glucagon-like peptide-1 receptor agonist, decreases glycosylated hemoglobin and causes weight loss. However, the cost of therapy and gastrointestinal side- effects such as nausea and diarrhea are important impediments to adherence and long-term compliance. We assessed the efficacy, safety and tolerability of low dose (0.6 mg) liraglutide in obese uncontrolled longstanding type 2 diabetes in Indian patients. Low dose liraglutide improved glycemic control and decreased weight. However, there was a significant drop out because of gastrointestinal intolerance and financial constraints.
Collapse
|
69
|
Ricotti V, Ridout DA, Scott E, Quinlivan R, Robb SA, Manzur AY, Muntoni F, Muntoni F, Robb S, Quinlivan R, Ricotti V, Main M, Bushby K, Straub V, Sarkozy A, Guglieri M, Strehle E, Eagle M, Mayhew A, Roper H, McMurchie H, Childs A, Pysden K, Pallant L, Spinty S, Peachey G, Shillington A, Wraige E, Jungbluth H, Sheehan J, Spahr R, Hughes I, Bateman E, Cammiss C, Willis T, Groves L, Emery N, Baxter P, Senior M, Hartley L, Parsons B, Majumdar A, Jenkins L, Naismith K, Keddie A, Horrocks I, Di Marco M, Chow G, Miah A, de Goede C, Thomas N, Geary M, Palmer J, White C, Greenfield K, Scott E. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry 2013; 84:698-705. [PMID: 23250964 DOI: 10.1136/jnnp-2012-303902] [Citation(s) in RCA: 173] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
OBJECTIVE To assess the current use of glucocorticoids (GCs) in Duchenne muscular dystrophy in the UK, and compare the benefits and the adverse events of daily versus intermittent prednisolone regimens. DESIGN A prospective longitudinal observational study across 17 neuromuscular centres in the UK of 360 boys aged 3-15 years with confirmed Duchenne muscular dystrophy who were treated with daily or intermittent (10 days on/10 days off) prednisolone for a mean duration of treatment of 4 years. RESULTS The median loss of ambulation was 12 years in intermittent and 14.5 years in daily treatment; the HR for intermittent treatment was 1.57 (95% CI 0.87 to 2.82). A fitted multilevel model comparing the intermittent and daily regiments for the NorthStar Ambulatory Assessment demonstrated a divergence after 7 years of age, with boys on an intermittent regimen declining faster (p<0.001). Moderate to severe side effects were more commonly reported and observed in the daily regimen, including Cushingoid features, adverse behavioural events and hypertension. Body mass index mean z score was higher in the daily regimen (1.99, 95% CI 1.79 to 2.19) than in the intermittent regimen (1.51, 95% CI 1.27 to 1.75). Height restriction was more severe in the daily regimen (mean z score -1.77, 95% CI -1.79 to -2.19) than in the intermittent regimen (mean z score -0.70, 95% CI -0.90 to -0.49). CONCLUSIONS Our study provides a framework for providing information to patients with Duchenne muscular dystrophy and their families when introducing GC therapy. The study also highlights the importance of collecting longitudinal natural history data on patients treated according to standardised protocols, and clearly identifies the benefits and the side-effect profile of two treatment regimens, which will help with informed choices and implementation of targeted surveillance.
Collapse
|
70
|
Shi F, Sivagnanam S, Folkerts M, Gautier Q, Jia X, Majumdar A, Jiang S. SU-E-T-242: A Gateway for GPU Computations in Radiotherapy. Med Phys 2013. [DOI: 10.1118/1.4814677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
71
|
Dey AK, Bhattacharya A, Majumdar A. Hepatitis C as a potential cause of IgA nephropathy. Indian J Nephrol 2013; 23:143-5. [PMID: 23716924 PMCID: PMC3658295 DOI: 10.4103/0971-4065.109443] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
This is a case report of a 16-year-old boy presenting with a history of oliguria and anasarca. Workup revealed marked proteinuria to the tune of 8 g/day. He was subsequently found to be hepatitis C positive. Genotype was hepatitis C virus type 6. Renal biopsy revealed mesangioproliferative glomerulonephritis with IgA deposits consistent with IgA nephropathy (IgAN). Initiation of oral ribavirin and pegylated interferon caused a marked reduction in proteinuria after 8 weeks of treatment. It was postulated that hepatitis C manifested as IgAN. This case report thus sheds light on the possibility of an association between hepatitis C and IgAN.
Collapse
|
72
|
Majumdar A, Saleh S, Hill S. A novel device for prolapse reduction. J OBSTET GYNAECOL 2013; 33:422. [DOI: 10.3109/01443615.2012.753419] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
73
|
Davidson AE, Siddiqui FM, Lopez MA, Lunt P, Carlson HA, Moore BE, Love S, Born DE, Roper H, Majumdar A, Jayadev S, Underhill HR, Smith CO, von der Hagen M, Hubner A, Jardine P, Merrison A, Curtis E, Cullup T, Jungbluth H, Cox MO, Winder TL, Abdel Salam H, Li JZ, Moore SA, Dowling JJ. Novel deletion of lysine 7 expands the clinical, histopathological and genetic spectrum of TPM2-related myopathies. ACTA ACUST UNITED AC 2013; 136:508-21. [PMID: 23413262 DOI: 10.1093/brain/aws344] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The β-tropomyosin gene encodes a component of the sarcomeric thin filament. Rod-shaped dimers of tropomyosin regulate actin-myosin interactions and β-tropomyosin mutations have been associated with nemaline myopathy, cap myopathy, Escobar syndrome and distal arthrogryposis types 1A and 2B. In this study, we expand the allelic spectrum of β-tropomyosin-related myopathies through the identification of a novel β-tropomyosin mutation in two clinical contexts not previously associated with β-tropomyosin. The first clinical phenotype is core-rod myopathy, with a β-tropomyosin mutation uncovered by whole exome sequencing in a family with autosomal dominant distal myopathy and muscle biopsy features of both minicores and nemaline rods. The second phenotype, observed in four unrelated families, is autosomal dominant trismus-pseudocamptodactyly syndrome (distal arthrogryposis type 7; previously associated exclusively with myosin heavy chain 8 mutations). In all four families, the mutation identified was a novel 3-bp in-frame deletion (c.20_22del) that results in deletion of a conserved lysine at the seventh amino acid position (p.K7del). This is the first mutation identified in the extreme N-terminus of β-tropomyosin. To understand the potential pathogenic mechanism(s) underlying this mutation, we performed both computational analysis and in vivo modelling. Our theoretical model predicts that the mutation disrupts the N-terminus of the α-helices of dimeric β-tropomyosin, a change predicted to alter protein-protein binding between β-tropomyosin and other molecules and to disturb head-to-tail polymerization of β-tropomyosin dimers. To create an in vivo model, we expressed wild-type or p.K7del β-tropomyosin in the developing zebrafish. p.K7del β-tropomyosin fails to localize properly within the thin filament compartment and its expression alters sarcomere length, suggesting that the mutation interferes with head-to-tail β-tropomyosin polymerization and with overall sarcomeric structure. We describe a novel β-tropomyosin mutation, two clinical-histopathological phenotypes not previously associated with β-tropomyosin and pathogenic data from the first animal model of β-tropomyosin-related myopathies.
Collapse
|
74
|
Majumdar A, Saleh S, Hill M, Hill SR. The impact of strenuous physical activity on the development of pelvic organ prolapse. J OBSTET GYNAECOL 2013; 33:115-9. [DOI: 10.3109/01443615.2012.721408] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
75
|
Arora N, Kalra A, Kausar H, Ghosh TK, Majumdar A. Primitive neuroectodermal tumour of uterine cervix - a diagnostic and therapeutic dilemma. J OBSTET GYNAECOL 2013; 32:711-3. [PMID: 22943734 DOI: 10.3109/01443615.2012.689028] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|